APO Research
Talk to an analyst

APO RESEARCH · REPORT

mRNA Vaccines for Infectious Diseases

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global mRNA Vaccines for Infectious Diseases Market Analysis and Forecast 2026-2032

19 December 2025199 pages

Choose your research edition.

Industry ResearchmRNA Vaccines for Infectious Diseases Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Vaccines for Infectious Diseases Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal mRNA Vaccines for Infectious Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Vaccines for Infectious Diseases Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Vaccines for Infectious Diseases Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global mRNA Vaccines for Infectious Diseases market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for mRNA Vaccines for Infectious Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for mRNA Vaccines for Infectious Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for mRNA Vaccines for Infectious Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for mRNA Vaccines for Infectious Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of mRNA Vaccines for Infectious Diseases include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for mRNA Vaccines for Infectious Diseases, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of mRNA Vaccines for Infectious Diseases, also provides the revenue of main regions and countries. Of the upcoming market potential for mRNA Vaccines for Infectious Diseases, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the mRNA Vaccines for Infectious Diseases revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global mRNA Vaccines for Infectious Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for mRNA Vaccines for Infectious Diseases revenue, projected growth trends, production technology, application and end-user industry.

mRNA Vaccines for Infectious Diseases Segment by Company

Translate Bio

Tiba Biotechnology

Sangamo Therapeutics

Moderna Therapeutics

In-Cell-Art

Ethris

eTheRNA

CureVac

BioNTech

Argos Therapeutics

mRNA Vaccines for Infectious Diseases Segment by Type

Infectious Disease Vaccines

Cancer Vaccines

mRNA Vaccines for Infectious Diseases Segment by Application

Infectious Disease

Cancer

mRNA Vaccines for Infectious Diseases Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines for Infectious Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines for Infectious Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines for Infectious Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of mRNA Vaccines for Infectious Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of mRNA Vaccines for Infectious Diseases company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Vaccines for Infectious Diseases revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Infectious Disease Vaccines Major Player Table 3. Cancer Vaccines Major Player Table 4. Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Infectious Disease Major Player Table 6. Cancer Major Player Table 7. mRNA Vaccines for Infectious Diseases Industry Trends Table 8. mRNA Vaccines for Infectious Diseases Industry Drivers Table 9. mRNA Vaccines for Infectious Diseases Industry Opportunities and Challenges Table 10. mRNA Vaccines for Infectious Diseases Industry Restraints Table 11. Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global mRNA Vaccines for Infectious Diseases Market Size by Region (2021-2026) & (US$ Million) Table 13. Global mRNA Vaccines for Infectious Diseases Market Share by Region (2021-2026) Table 14. Global mRNA Vaccines for Infectious Diseases Market Size by Region (2027-2032) & (US$ Million) Table 15. Global mRNA Vaccines for Infectious Diseases Market Share by Region (2027-2032) Table 16. Global mRNA Vaccines for Infectious Diseases Revenue by Players (US$ Million) & (2021-2026) Table 17. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Players (2021-2026) Table 18. Global mRNA Vaccines for Infectious Diseases Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global mRNA Vaccines for Infectious Diseases Key Players Headquarters & Area Served Table 20. Global mRNA Vaccines for Infectious Diseases Players, Product Type & Application Table 21. Global mRNA Vaccines for Infectious Diseases Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global mRNA Vaccines for Infectious Diseases by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global mRNA Vaccines for Infectious Diseases Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026) & (US$ Million) Table 26. Global mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032) & (US$ Million) Table 27. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2021-2026) Table 28. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2027-2032) Table 29. Global mRNA Vaccines for Infectious Diseases Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026) & (US$ Million) Table 31. Global mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032) & (US$ Million) Table 32. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2021-2026) Table 33. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2027-2032) Table 34. Translate Bio Company Information Table 35. Translate Bio Business Overview Table 36. Translate Bio mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Translate Bio mRNA Vaccines for Infectious Diseases Product Portfolio Table 38. Translate Bio Recent Development Table 39. Tiba Biotechnology Company Information Table 40. Tiba Biotechnology Business Overview Table 41. Tiba Biotechnology mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Tiba Biotechnology mRNA Vaccines for Infectious Diseases Product Portfolio Table 43. Tiba Biotechnology Recent Development Table 44. Sangamo Therapeutics Company Information Table 45. Sangamo Therapeutics Business Overview Table 46. Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio Table 48. Sangamo Therapeutics Recent Development Table 49. Moderna Therapeutics Company Information Table 50. Moderna Therapeutics Business Overview Table 51. Moderna Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Moderna Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio Table 53. Moderna Therapeutics Recent Development Table 54. In-Cell-Art Company Information Table 55. In-Cell-Art Business Overview Table 56. In-Cell-Art mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. In-Cell-Art mRNA Vaccines for Infectious Diseases Product Portfolio Table 58. In-Cell-Art Recent Development Table 59. Ethris Company Information Table 60. Ethris Business Overview Table 61. Ethris mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Ethris mRNA Vaccines for Infectious Diseases Product Portfolio Table 63. Ethris Recent Development Table 64. eTheRNA Company Information Table 65. eTheRNA Business Overview Table 66. eTheRNA mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. eTheRNA mRNA Vaccines for Infectious Diseases Product Portfolio Table 68. eTheRNA Recent Development Table 69. CureVac Company Information Table 70. CureVac Business Overview Table 71. CureVac mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. CureVac mRNA Vaccines for Infectious Diseases Product Portfolio Table 73. CureVac Recent Development Table 74. BioNTech Company Information Table 75. BioNTech Business Overview Table 76. BioNTech mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. BioNTech mRNA Vaccines for Infectious Diseases Product Portfolio Table 78. BioNTech Recent Development Table 79. Argos Therapeutics Company Information Table 80. Argos Therapeutics Business Overview Table 81. Argos Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Argos Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio Table 83. Argos Therapeutics Recent Development Table 84. North America mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026) & (US$ Million) Table 85. North America mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032) & (US$ Million) Table 86. North America mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026) & (US$ Million) Table 87. North America mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032) & (US$ Million) Table 88. North America mRNA Vaccines for Infectious Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. North America mRNA Vaccines for Infectious Diseases Revenue by Country (2021-2026) & (US$ Million) Table 90. North America mRNA Vaccines for Infectious Diseases Revenue by Country (US$ Million) & (2027-2032) Table 91. Europe mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026) & (US$ Million) Table 92. Europe mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032) & (US$ Million) Table 93. Europe mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026) & (US$ Million) Table 94. Europe mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032) & (US$ Million) Table 95. Europe mRNA Vaccines for Infectious Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Europe mRNA Vaccines for Infectious Diseases Revenue by Country (2021-2026) & (US$ Million) Table 97. Europe mRNA Vaccines for Infectious Diseases Revenue by Country (US$ Million) & (2027-2032) Table 98. China mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026) & (US$ Million) Table 99. China mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032) & (US$ Million) Table 100. China mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026) & (US$ Million) Table 101. China mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026) & (US$ Million) Table 103. Asia mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032) & (US$ Million) Table 104. Asia mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026) & (US$ Million) Table 105. Asia mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia mRNA Vaccines for Infectious Diseases Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Asia mRNA Vaccines for Infectious Diseases Revenue by Region (US$ Million) & (2021-2026) Table 108. Asia mRNA Vaccines for Infectious Diseases Revenue by Region (US$ Million) & (2027-2032) Table 109. SAMEA mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026) & (US$ Million) Table 110. SAMEA mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032) & (US$ Million) Table 111. SAMEA mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026) & (US$ Million) Table 112. SAMEA mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032) & (US$ Million) Table 113. SAMEA mRNA Vaccines for Infectious Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. SAMEA mRNA Vaccines for Infectious Diseases Revenue by Country (2021-2026) & (US$ Million) Table 115. SAMEA mRNA Vaccines for Infectious Diseases Revenue by Country (US$ Million) & (2027-2032) Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. mRNA Vaccines for Infectious Diseases Image Figure 2. Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Vaccines for Infectious Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 4. Infectious Disease Vaccines Image Figure 5. Cancer Vaccines Image Figure 6. Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global mRNA Vaccines for Infectious Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 8. Infectious Disease Image Figure 9. Cancer Image Figure 10. Global mRNA Vaccines for Infectious Diseases Market Size (US$ Million) & (2021-2032) Figure 11. Global mRNA Vaccines for Infectious Diseases Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global mRNA Vaccines for Infectious Diseases Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global mRNA Vaccines for Infectious Diseases Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global mRNA Vaccines for Infectious Diseases Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global mRNA Vaccines for Infectious Diseases Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2021-2032) Figure 18. Global mRNA Vaccines for Infectious Diseases Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2021-2032) Figure 21. North America mRNA Vaccines for Infectious Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032) Figure 23. North America mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032) Figure 24. North America mRNA Vaccines for Infectious Diseases Revenue Share by Country (2021-2032) Figure 25. United States mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe mRNA Vaccines for Infectious Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032) Figure 30. Europe mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032) Figure 31. Europe mRNA Vaccines for Infectious Diseases Revenue Share by Country (2021-2032) Figure 32. Germany mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China mRNA Vaccines for Infectious Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032) Figure 42. China mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032) Figure 43. Asia mRNA Vaccines for Infectious Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032) Figure 45. Asia mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032) Figure 46. Asia mRNA Vaccines for Infectious Diseases Revenue Share by Region (2021-2032) Figure 47. Japan mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA mRNA Vaccines for Infectious Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032) Figure 55. SAMEA mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032) Figure 56. SAMEA mRNA Vaccines for Infectious Diseases Revenue Share by Country (2021-2032) Figure 57. Brazil mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt mRNA Vaccines for Infectious Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Infectious Disease Vaccines
  • Cancer Vaccines
Applications
  • Infectious Disease
  • Cancer
Companies covered
  • Translate Bio
  • Tiba Biotechnology
  • Sangamo Therapeutics
  • Moderna Therapeutics
  • In-Cell-Art
  • Ethris
  • eTheRNA
  • CureVac
  • BioNTech
  • Argos Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 mRNA Vaccines for Infectious Diseases Market by Type
  3. 1.2.1 Global mRNA Vaccines for Infectious Diseases Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Infectious Disease Vaccines
  5. 1.2.3 Cancer Vaccines
  6. 1.3 mRNA Vaccines for Infectious Diseases Market by Application
  7. 1.3.1 Global mRNA Vaccines for Infectious Diseases Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Infectious Disease
  9. 1.3.3 Cancer
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 mRNA Vaccines for Infectious Diseases Market Dynamics
  1. 2.1 mRNA Vaccines for Infectious Diseases Industry Trends
  2. 2.2 mRNA Vaccines for Infectious Diseases Industry Drivers
  3. 2.3 mRNA Vaccines for Infectious Diseases Industry Opportunities and Challenges
  4. 2.4 mRNA Vaccines for Infectious Diseases Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global mRNA Vaccines for Infectious Diseases Market Perspective (2021-2032)
  2. 3.2 Global mRNA Vaccines for Infectious Diseases Growth Trends by Region
  3. 3.2.1 Global mRNA Vaccines for Infectious Diseases Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global mRNA Vaccines for Infectious Diseases Market Size by Region (2021-2026)
  5. 3.2.3 Global mRNA Vaccines for Infectious Diseases Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global mRNA Vaccines for Infectious Diseases Revenue by Players
  2. 4.1.1 Global mRNA Vaccines for Infectious Diseases Revenue by Players (2021-2026)
  3. 4.1.2 Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global mRNA Vaccines for Infectious Diseases Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global mRNA Vaccines for Infectious Diseases Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global mRNA Vaccines for Infectious Diseases Key Players Headquarters & Area Served
  7. 4.4 Global mRNA Vaccines for Infectious Diseases Players, Product Type & Application
  8. 4.5 Global mRNA Vaccines for Infectious Diseases Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global mRNA Vaccines for Infectious Diseases Market CR5 and HHI
  11. 4.6.3 2025 mRNA Vaccines for Infectious Diseases Tier 1, Tier 2, and Tier 3
5 mRNA Vaccines for Infectious Diseases Market Size by Type
  1. 5.1 Global mRNA Vaccines for Infectious Diseases Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2032)
  3. 5.3 Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Type (2021-2032)
6 mRNA Vaccines for Infectious Diseases Market Size by Application
  1. 6.1 Global mRNA Vaccines for Infectious Diseases Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2032)
  3. 6.3 Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Translate Bio
  2. 7.1.1 Translate Bio Company Information
  3. 7.1.2 Translate Bio Business Overview
  4. 7.1.3 Translate Bio mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Translate Bio mRNA Vaccines for Infectious Diseases Product Portfolio
  6. 7.1.5 Translate Bio Recent Developments
  7. 7.2 Tiba Biotechnology
  8. 7.2.1 Tiba Biotechnology Company Information
  9. 7.2.2 Tiba Biotechnology Business Overview
  10. 7.2.3 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Product Portfolio
  12. 7.2.5 Tiba Biotechnology Recent Developments
  13. 7.3 Sangamo Therapeutics
  14. 7.3.1 Sangamo Therapeutics Company Information
  15. 7.3.2 Sangamo Therapeutics Business Overview
  16. 7.3.3 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
  18. 7.3.5 Sangamo Therapeutics Recent Developments
  19. 7.4 Moderna Therapeutics
  20. 7.4.1 Moderna Therapeutics Company Information
  21. 7.4.2 Moderna Therapeutics Business Overview
  22. 7.4.3 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
  24. 7.4.5 Moderna Therapeutics Recent Developments
  25. 7.5 In-Cell-Art
  26. 7.5.1 In-Cell-Art Company Information
  27. 7.5.2 In-Cell-Art Business Overview
  28. 7.5.3 In-Cell-Art mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  29. 7.5.4 In-Cell-Art mRNA Vaccines for Infectious Diseases Product Portfolio
  30. 7.5.5 In-Cell-Art Recent Developments
  31. 7.6 Ethris
  32. 7.6.1 Ethris Company Information
  33. 7.6.2 Ethris Business Overview
  34. 7.6.3 Ethris mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Ethris mRNA Vaccines for Infectious Diseases Product Portfolio
  36. 7.6.5 Ethris Recent Developments
  37. 7.7 eTheRNA
  38. 7.7.1 eTheRNA Company Information
  39. 7.7.2 eTheRNA Business Overview
  40. 7.7.3 eTheRNA mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  41. 7.7.4 eTheRNA mRNA Vaccines for Infectious Diseases Product Portfolio
  42. 7.7.5 eTheRNA Recent Developments
  43. 7.8 CureVac
  44. 7.8.1 CureVac Company Information
  45. 7.8.2 CureVac Business Overview
  46. 7.8.3 CureVac mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  47. 7.8.4 CureVac mRNA Vaccines for Infectious Diseases Product Portfolio
  48. 7.8.5 CureVac Recent Developments
  49. 7.9 BioNTech
  50. 7.9.1 BioNTech Company Information
  51. 7.9.2 BioNTech Business Overview
  52. 7.9.3 BioNTech mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  53. 7.9.4 BioNTech mRNA Vaccines for Infectious Diseases Product Portfolio
  54. 7.9.5 BioNTech Recent Developments
  55. 7.10 Argos Therapeutics
  56. 7.10.1 Argos Therapeutics Company Information
  57. 7.10.2 Argos Therapeutics Business Overview
  58. 7.10.3 Argos Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Argos Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
  60. 7.10.5 Argos Therapeutics Recent Developments
8 North America
  1. 8.1 North America mRNA Vaccines for Infectious Diseases Revenue (2021-2032)
  2. 8.2 North America mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2032)
  3. 8.2.1 North America mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026)
  4. 8.2.2 North America mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032)
  5. 8.3 North America mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032)
  6. 8.4 North America mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2032)
  7. 8.4.1 North America mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026)
  8. 8.4.2 North America mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032)
  9. 8.5 North America mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032)
  10. 8.6 North America mRNA Vaccines for Infectious Diseases Revenue by Country
  11. 8.6.1 North America mRNA Vaccines for Infectious Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America mRNA Vaccines for Infectious Diseases Revenue by Country (2021-2026)
  13. 8.6.3 North America mRNA Vaccines for Infectious Diseases Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe mRNA Vaccines for Infectious Diseases Revenue (2021-2032)
  2. 9.2 Europe mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2032)
  3. 9.2.1 Europe mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026)
  4. 9.2.2 Europe mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032)
  5. 9.3 Europe mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032)
  6. 9.4 Europe mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2032)
  7. 9.4.1 Europe mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026)
  8. 9.4.2 Europe mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032)
  9. 9.5 Europe mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032)
  10. 9.6 Europe mRNA Vaccines for Infectious Diseases Revenue by Country
  11. 9.6.1 Europe mRNA Vaccines for Infectious Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe mRNA Vaccines for Infectious Diseases Revenue by Country (2021-2026)
  13. 9.6.3 Europe mRNA Vaccines for Infectious Diseases Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China mRNA Vaccines for Infectious Diseases Revenue (2021-2032)
  2. 10.2 China mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2032)
  3. 10.2.1 China mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026)
  4. 10.2.2 China mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032)
  5. 10.3 China mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032)
  6. 10.4 China mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2032)
  7. 10.4.1 China mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026)
  8. 10.4.2 China mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032)
  9. 10.5 China mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia mRNA Vaccines for Infectious Diseases Revenue (2021-2032)
  2. 11.2 Asia mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2032)
  3. 11.2.1 Asia mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026)
  4. 11.2.2 Asia mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032)
  5. 11.3 Asia mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032)
  6. 11.4 Asia mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2032)
  7. 11.4.1 Asia mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026)
  8. 11.4.2 Asia mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032)
  9. 11.5 Asia mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032)
  10. 11.6 Asia mRNA Vaccines for Infectious Diseases Revenue by Country
  11. 11.6.1 Asia mRNA Vaccines for Infectious Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia mRNA Vaccines for Infectious Diseases Revenue by Country (2021-2026)
  13. 11.6.3 Asia mRNA Vaccines for Infectious Diseases Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA mRNA Vaccines for Infectious Diseases Revenue (2021-2032)
  2. 12.2 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Type (2027-2032)
  5. 12.3 SAMEA mRNA Vaccines for Infectious Diseases Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Application (2027-2032)
  9. 12.5 SAMEA mRNA Vaccines for Infectious Diseases Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Country
  11. 12.6.1 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA mRNA Vaccines for Infectious Diseases Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst